CLGN News & Events

CollPlant announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market. The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The Korean patent allowance follows the recent grant of a Japanese patent covering, among other things, a photocurable dermal filler kit and related polymerizable compositions comprising chemically modified rhCollagen for use in tissue augmentation. CollPlant's photocuring technology is further protected by granted patents in the United States, Europe, China, Brazil, Australia, and Israel, with additional applications pending in other territories.

CollPlant Biotechnologies announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1.6M of the company's ordinary shares at a purchase price of $1.25 per share in a registered direct offering. In addition, in a concurrent private placement, the company will issue unregistered series A warrants to purchase up to 1.6M ordinary shares and unregistered series B warrants to purchase up to 1.6M ordinary shares. The series A warrants will have an exercise price of $1.25 per share, will be exercisable immediately and will expire five years after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The series B warrants will have an exercise price of $1.25 per share, will be exercisable immediately and will expire eighteen months after the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The offering is expected to close on or about February 6, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the company, are expected to be approximately $2M.

CollPlant files $100M mixed securities shelf